Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

bluebird bio Company Profile (NASDAQ:BLUE)

Consensus Ratings for bluebird bio (NASDAQ:BLUE) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $52.75 (28.66% upside)

Analysts' Ratings History for bluebird bio (NASDAQ:BLUE)
Show:
DateFirmActionRatingPrice TargetDetailsShare
9/22/2014Roth CapitalInitiated CoverageBuy$50.00ViewTweet This Rating  Share This Rating on StockTwits
9/4/2014SunTrustInitiated CoverageBuy$57.00ViewTweet This Rating  Share This Rating on StockTwits
6/18/2014JPMorgan Chase & Co.Reiterated RatingOverweight$44.00 -> $53.00ViewTweet This Rating  Share This Rating on StockTwits
6/16/2014WedbushBoost Price Target$51.00ViewTweet This Rating  Share This Rating on StockTwits
6/13/2014Piper JaffrayInitiated CoverageOverweightViewTweet This Rating  Share This Rating on StockTwits
7/30/2013Cowen and CompanyInitiated CoverageOutperform$44.00ViewTweet This Rating  Share This Rating on StockTwits
7/15/2013WedbushInitiated CoverageOutperformViewTweet This Rating  Share This Rating on StockTwits
7/15/2013Canaccord GenuityInitiated CoverageBuy$45.00ViewTweet This Rating  Share This Rating on StockTwits
7/15/2013JPMorgan Chase & Co.Initiated CoverageOverweight$44.00ViewTweet This Rating  Share This Rating on StockTwits
7/15/2013Bank of AmericaInitiated CoverageBuy$42.00ViewTweet This Rating  Share This Rating on StockTwits
(Data available from 10/25/2012 forward)
Discuss bluebird bio